Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 7/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7149083 | 0.82 | — | — | |
| SCHEMBL7144825 | 0.75 | TK1 (0.42) | — | |
| SCHEMBL7147950 | 0.73 | RECQL (0.43) | CYP1A2KMOCHRM2CHRM1CHRM3 | |
| SCHEMBL7139055 | 0.73 | — | — | |
| SCHEMBL7149316 | 0.72 | KDM4E (0.39) | RECQLHTR2AHTR2CHTR2B | |
| SCHEMBL7147277 | 0.71 | PARP14 (0.30) | — | |
| SCHEMBL8729507 | 0.69 | — | — | |
| SCHEMBL8461046 | 0.68 | CYP1A2 (0.38) | CYP1A2KMORECQL | |
| SCHEMBL7142477 | 0.63 | CTSS (0.32) | — | |
| SCHEMBL7146920 | 0.63 | SMN1; SMN2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | COOK PHILLIP D (US) | 2003-04-03 | — | — | US | disclosed |
| US-6448373-B1 | INHIBITORS OF ENZYMES SUCH AS PHOSPHOLIPASE A2; TREATMENT OF INFLAMMATORY DISEASES INCLUDING ATOPIC DERMATITIS AND INFLAMMATORY BOWEL DISEASE | ISIS PHARMACEUTICALS, INC. | 2002-09-10 | — | — | US | disclosed |
| EP-0739351-B1 | MONOMERIC DIOLS AND PHOSPHATE LINKED OLIGOMERS FORMED THEREFROM | ISIS PHARMACEUTICALS INC (US) | 2002-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065146-A1 | Monomeric diols, phosphate linked oligomers formed therefrom and processes for preparing | BPGM, PPIP5K2, PGM2 | CYP1A2 4787/4885KMO 3745/4885CHRM2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.